<DOC>
	<DOCNO>NCT02640404</DOCNO>
	<brief_summary>The aim study assess safety Menactra vaccine infant , toddler , child , adolescent , adult Objective : - To describe safety profile dose ( applicable ) Menactra vaccine participant age 9 month 55 year registration .</brief_summary>
	<brief_title>Safety Meningococcal ( Groups A , C , Y W-135 ) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Healthy Subjects Vietnam</brief_title>
	<detailed_description>Infants toddler receive 2 dos vaccine 3 month apart . Children ≥ 2 year adults age 55 year receive single dose vaccine . All participant evaluate safety 28 day post-vaccination</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 9 month 55 year day first study visit For adult : Informed consent form sign dated subject . For minor : Informed consent form sign dated parent legally acceptable representative . In addition , accordance Independent Ethics Committee /Institutional Review Board requirement appropriate age subject , subject may require sign date inform consent form age 12 17 year assent form age 8 11 year . Subject and/or parent/legally acceptable representative ( applicable ) able attend schedule visit comply study procedure . Participation time study enrollment ( 4 week precede study vaccination ) plan participation present study period another clinical study investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede study vaccination plan receipt vaccine 4 week follow study vaccination . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( ≥ 2mg/kg/day prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use study vaccine contain substance Laboratoryconfirmed , selfreported , know ( report parent/legally acceptable representative ) thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Personal history GuillainBarré syndrome Chronic illness , opinion investigator , stage might interfere study conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 37.5°C ≤ 35.5°C ) . A prospective subject include study condition resolve febrile event subside . Identified natural adopt child Investigator employee direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Meningococcal Vaccine</keyword>
</DOC>